Inventor · disambiguated record
Ekkehard Moessner
Also filed as: MOESSNER EKKEHARD
96 granted patents·99 pending applications·1,330 citations·filing 2009–2025
99Inventor score
Top patents by PatentIndex Score
195 records- 0198US11130822B2ImmunoconjugatesROCHE GLYCART AG·Filed 2019·Granted Sep 28, 2021·16 cites·24 claims
- 0298US10316104B2ImmunoconjugatesROCHE GLYCART AG·Filed 2016·Granted Jun 11, 2019·30 cites·23 claims
- 0398US10202464B2ImmunoconjugatesROCHE GLYCART AG·Filed 2016·Granted Feb 12, 2019·30 cites·3 claims
- 0498US10184009B2Mutant interleukin-2 polypeptidesROCHE GLYCART AG·Filed 2017·Granted Jan 22, 2019·37 cites·30 claims
- 0598US9447159B2ImmunoconjugatesAST OLIVER·Filed 2012·Granted Sep 20, 2016·111 cites·27 claims
- 0697US11306154B2Methods of treating cancer by administering antigen-binding molecules comprising a TNF family ligand trimerHOFFMANN LA ROCHE·Filed 2019·Granted Apr 19, 2022·13 cites·56 claims
- 0797US11267903B2Antigen-binding molecules comprising a tumor necrosis factor (TNF) family ligand trimerHOFFMANN LA ROCHE·Filed 2019·Granted Mar 8, 2022·17 cites·46 claims
- 0897US10577429B2Anti-FAP antibodies and methods of useROCHE GLYCART AG·Filed 2015·Granted Mar 3, 2020·17 cites·28 claims
- 0997US10464981B2Tumor necrosis factor (TNF) family ligand trimer-containing antigen binding moleculesHOFFMANN LA ROCHE·Filed 2016·Granted Nov 5, 2019·33 cites·22 claims
- 1097US10323098B2Mutant interleukin-2 polypeptidesROCHE GLYCART AG·Filed 2016·Granted Jun 18, 2019·25 cites·30 claims
- 1197US10253110B2Anti-FAP antibodies and methods of useROCHE GLYCART AG·Filed 2015·Granted Apr 9, 2019·15 cites·17 claims
- 1297US9382323B2Multispecific antibodies comprising full length antibodies and single chain fab fragmentsBRINKMANN ULRICH·Filed 2010·Granted Jul 5, 2016·77 cites·22 claims
- 1397US9266938B2Mutant interleukin-2 polypeptidesAST OLIVER·Filed 2012·Granted Feb 23, 2016·123 cites·25 claims
- 1497US8969526B2Antibody Fc variantsBAEHNER MONIKA·Filed 2012·Granted Mar 3, 2015·226 cites·8 claims
- 1596US11111312B2Mutant interleukin-2 polypeptidesROCHE GLYCART AG·Filed 2018·Granted Sep 7, 2021·8 cites·5 claims
- 1696US10683368B2Fc-region variants with modified FcRn-binding and methods of useHOFFMANN LA ROCHE·Filed 2017·Granted Jun 16, 2020·13 cites·12 claims
- 1796US10392445B2Tumor necrosis factor (TNF) family ligand trimer-containing antigen-binding moleculesHOFFMANN LA ROCHE·Filed 2016·Granted Aug 27, 2019·31 cites·39 claims
- 1896US9206260B2Anti-CEA antibodiesROCHE GLYCART AG·Filed 2013·Granted Dec 8, 2015·23 cites·13 claims
- 1995US11780920B2Antibodies binding to CD3 and CD19HOFFMANN LA ROCHE·Filed 2021·Granted Oct 10, 2023·4 cites·59 claims
- 2095US11286300B2Humanized anti-human CD19 antibodies and methods of useHOFFMANN LA ROCHE·Filed 2016·Granted Mar 29, 2022·11 cites·8 claims
- 2195US11149083B2Antigen binding molecules comprising a TNF family ligand trimer and a Tenascin binding moietyHOFFMANN—LA ROCHE INC·Filed 2018·Granted Oct 19, 2021·12 cites·25 claims
- 2295US9346872B2Interleukin-10 fusion proteinsROCHE GLYCART AG·Filed 2013·Granted May 24, 2016·43 cites·22 claims
- 2395US8642742B2Anti-CEA antibodiesHOFER THOMAS U·Filed 2012·Granted Feb 4, 2014·38 cites·18 claims
- 2494US11332545B2Anti-FAP antibodies and methods of useROCHE GLYCART AG·Filed 2019·Granted May 17, 2022·6 cites·9 claims
- 2594US10683369B2Monoclonal antibodies against BCMAENGMAB SARL·Filed 2016·Granted Jun 16, 2020·14 cites·21 claims
- 2694US9890204B2Trivalent, bispecific antibodiesBRINKMANN ULRICH·Filed 2012·Granted Feb 13, 2018·27 cites·11 claims
- 2794US9011847B2Anti-FAP antibodies and methods of useBACAC MARINA·Filed 2011·Granted Apr 21, 2015·34 cites·26 claims
- 2893US11591397B2Bispecific antibody molecules binding to CD3 and EGFRvIIIHOFFMANN LA ROCHE·Filed 2021·Granted Feb 28, 2023·2 cites·15 claims
- 2993US10781258B2Bispecific T cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2018·Granted Sep 22, 2020·4 cites·39 claims
- 3093US10155815B2Bispecific T cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2014·Granted Dec 18, 2018·12 cites·46 claims
- 3193US8003099B2Antibodies against human IL17 and uses thereofROCHE PALO ALTO LLC·Filed 2009·Granted Aug 23, 2011·44 cites·17 claims
- 3292US12215155B2Antibodies binding to CD3 and CD19HOFFMANN LA ROCHE·Filed 2023·Granted Feb 4, 2025·1 cites·64 claims
- 3392US11608376B2Tumor-targeted agonistic CD28 antigen binding moleculesHOFFMANN LA ROCHE·Filed 2019·Granted Mar 21, 2023·14 cites·49 claims
- 3492US9963513B2Method for the selection of antibodies against BCMAENGMAB AG·Filed 2014·Granted May 8, 2018·19 cites·5 claims
- 3592US9771427B2ASGPR antibodies and uses thereofROCHE GLYCART AG·Filed 2013·Granted Sep 26, 2017·16 cites·25 claims
- 3691US11788205B2Car-t cell assay for specificity test of novel antigen binding moietiesHOFFMANN LA ROCHE·Filed 2020·Granted Oct 17, 2023·3 cites·21 claims
- 3791US11459404B2Bispecific T cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2017·Granted Oct 4, 2022·5 cites·1 claims
- 3891US10822402B2Humanized anti-tau(pS422) antibodies and methods of useHOFFMANN LA ROCHE·Filed 2017·Granted Nov 3, 2020·4 cites·12 claims
- 3991US10323099B2Multispecific domain exchanged common variable light chain antibodiesHOFFMANN LA ROCHE·Filed 2016·Granted Jun 18, 2019·13 cites·12 claims
- 4090US11214622B2Antibodies specific for DR5 and methods of useROCHE GLYCART AG·Filed 2018·Granted Jan 4, 2022·6 cites·13 claims
- 4190US9926379B2Bispecific antibodies specific for FAP and DR5, antibodies specific for DR5ROCHE GLYCART AG·Filed 2014·Granted Mar 27, 2018·17 cites·28 claims
- 4289US10562949B2Interleukin-2 fusion proteins and uses thereofROCHE GLYCART AG·Filed 2017·Granted Feb 18, 2020·6 cites·10 claims
- 4389US10364292B2Monovalent blood brain barrier shuttle modulesHOFFMANN LA ROCHE·Filed 2016·Granted Jul 30, 2019·10 cites·10 claims
- 4488US11098099B2Interleukin-2 fusion proteins and uses thereofHOFFMANN LA ROCHE·Filed 2015·Granted Aug 24, 2021·5 cites·28 claims
- 4588US10040843B2Interleukin-10 fusion proteins and uses thereofROCHE GLYCART AG·Filed 2016·Granted Aug 7, 2018·7 cites·22 claims
- 4688US9650442B2Bispecific anti-EGFR/anti IGF-1R antibodiesROCHE GLYCART AG·Filed 2014·Granted May 16, 2017·14 cites·6 claims
- 4788US2025043028A1Bispecific t cell activating antigen binding moleculesROCHE GLYCART AG·Filed 2024·Application pending·0 cites
- 4887US11679127B2Antigen binding receptors specific for mutated Fc domainsHOFFMANN LA ROCHE·Filed 2019·Granted Jun 20, 2023·3 cites·31 claims
- 4987US10253104B2Bispecific antibodies against CD3ϵ and BCMAENGMAB AG·Filed 2015·Granted Apr 9, 2019·10 cites·16 claims
- 5087US9481730B2DR5—FAP bispecific death receptor agonistic antibodiesBRUENKER PETER·Filed 2010·Granted Nov 1, 2016·29 cites·9 claims
Showing the top 50 of 195 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Ekkehard Moessner files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →